The efficacy of tofacitinib/Shangjie in the treatment of rheumatoid arthritis

Tofacitinib/Shangjie(Tofacitinib), as a JAK inhibitor, is an important representative in the treatment field of rheumatoid arthritis. In the International Rheumatology and Immunology Guidelines, tofacitinib is positioned as indicated for patients with moderate to severe rheumatoid arthritis who have an inadequate response to conventional DMARDs such as methotrexate. Because its mechanism directly acts on the inflammatory signaling pathway and can regulate the immune response from the source, it has shown a prominent therapeutic advantage in rheumatoid treatment.

Rheumatoid arthritis is a chronic, autoimmune disease characterized by joint synovial inflammation, morning stiffness, joint redness, swelling and pain, and even functional limitation. Tofacitinib blocks the signaling of multiple pro-inflammatory cytokines by inhibiting the JAK pathway, reducing inflammation levels, thereby improving joint pain, reducing swelling, and increasing range of motion. After using tofacitinib, most patients have significantly shortened morning stiffness, reduced joint stiffness, and become more flexible in daily life movements. This is a significant change that has been repeatedly verified by overseas real-world studies.

Tofacitinib also slows structural damage to joints, which is extremely valuable in rheumatoid treatment. If traditional treatment cannot effectively control inflammation, it may easily lead to joint damage or even deformity in the long term. Tofacitinib can participate in the process of joint destruction by inhibiting the inflammatory pathway, providing patients with the possibility of preserving long-term joint function. In overseas guidelines, tofacitinib is often considered an important follow-up treatment option if patients still have high disease activity after using traditional DMARDs.

In addition, tofacitinib is an oral drug, which is more convenient than biological agents that require injection, reducing the patient's pain and medical time costs caused by frequent injections. For rheumatoid patients who require long-term maintenance treatment, oral administration improves compliance and makes the treatment experience easier, which has significant real-life advantages.

Reference materials:https://www.xeljanz.com/